Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | ADA | P00813 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 5/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | AHCY | P23526 | 6/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18521198 | 0.88 | ADORA2A (0.41) | ADORA2AADORA2BADORA1ADARET | |
| SCHEMBL18520803 | 0.75 | LMNA (0.53) | ADORA2AADORA2BADORA1ADASMN1; SMN2 | |
| SCHEMBL21539463 | 0.73 | ADA (0.36) | ADAKDR | |
| SCHEMBL23843794 | 0.71 | ADORA2A (0.41) | ADORA2AADORA2BADORA1ADAAHCY | |
| SCHEMBL21539443 | 0.71 | ADA (0.54) | ADORA2AADORA2BADORA1ADASMN1; SMN2 | |
| SCHEMBL23185942 | 0.71 | ADORA2A (0.47) | ADORA2AADORA2BADORA1AHCY | |
| SCHEMBL24499103 | 0.69 | AHCY (0.41) | ADORA2AADORA2BADORA1SMN1; SMN2AHCY | |
| SCHEMBL23619352 | 0.69 | NR4A2 (0.30) | — | |
| SCHEMBL16747750 | 0.66 | ADA (0.56) | ADORA2AADORA2BADORA1ADASMN1; SMN2 | |
| SCHEMBL14134333 | 0.64 | KDR (0.37) | ADARETKDRSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738074-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738074-B2 | Cyclic di-nucleotide compounds as STING agonists | STING1, CGAS, IFNAR1 | ADORA2A 72/4885ADORA2B 150/4885ADORA1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.